First-Quarter 2024 Financial Results Released by AbbVie
AbbVie (NYSE: ABBV) has released its financial results for the first quarter ending March 31, 2024. Richard A. Gonzalez, the chairman and CEO of AbbVie, expressed satisfaction with the company’s…
Neurocrine Biosciences Launches C@H?! Initiative for Congenital Adrenal Hyperplasia Support
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has unveiled the launch of WHAT THE C@H?!, an educational initiative designed to address the information gap surrounding congenital adrenal hyperplasia (CAH) and acknowledge the…
Bio-Techne Initiates Patent Infringement Lawsuit Against Molecular Instruments
Bio-Techne Corporation (NASDAQ: TECH), a renowned global life sciences company specializing in innovative tools and bioactive reagents for both research and clinical diagnostics, has officially initiated legal proceedings in the…
Moderna Teams Up with OpenAI to Propel mRNA Medicine Innovation
Moderna, Inc. (NASDAQ: MRNA) and OpenAI have announced a collaborative effort aimed at harnessing the potential of artificial intelligence (AI) to revolutionize both business and healthcare. Moderna, known for its…
CVS Health Allocates $19.2 Million Towards Affordable Housing in Arvada, Colorado
CVS Health® (NYSE: CVS) revealed today a significant investment of $19.2 million, facilitated via Boston Financial, earmarked for the construction of 85 new affordable housing units in Arvada, Colorado. This…
Native Health Navigator Program Connects Tribes to Cancer Care
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics have announced an exclusive licensing agreement, granting Vertex access to TreeFrog’s cutting-edge cell manufacturing technology, C-Stem™. This collaboration aims to optimize the…
Vertex, TreeFrog Therapeutics Collaborate to Enhance Cell Therapy Production for Type 1 Diabetes
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics have announced an exclusive licensing agreement, granting Vertex access to TreeFrog’s cutting-edge cell manufacturing technology, C-Stem™. This collaboration aims to optimize the…
Roche Q1 Sales Up 2% (CER), Both Divisions Show High Single-Digit Growth Excluding COVID-19
Roche Reports 2% Growth in Group Sales Despite Currency Impact In the first quarter of 2024, Roche saw a 2% increase in group sales at constant exchange rates (CER), though…
Novel Malaria Treatment Shows Positive Results for Infants <5kg: Novartis & Medicines for Malaria Venture
Novartis and Medicines for Malaria Venture (MMV) have unveiled encouraging results from their phase II/III CALINA trial, indicating that a newly formulated version of Coartem® (artemether-lumefantrine) tailored for infants weighing…
EU Approves Vaidya as Additional Therapy for Adults with PNH and Persistent Haemolytic Anaemia Despite Rovelizumab or Eculizumab Treatment
Voydeya (danicopan) Receives EU Approval as Supplemental Treatment for Adults with PNH and Residual Hemolytic Anemia Voydeya (danicopan) has gained approval in the European Union (EU) to be used alongside…
Join Allergan Aesthetics in Becoming the Ambassador for BOTOX® Cosmetic and Their Leading Brands
Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), is extending an invitation to consumers to participate in future campaigns featuring their flagship brands, such as BOTOX® Cosmetic, the JUVÉDERM® Collection…
Positive Phase 2 Results for NBI-1065845 in Adult Major Depression
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has unveiled positive top-line results from its Phase 2 SAVITRI™ trial. This study, employing a randomized, double-blind, and placebo-controlled design, evaluated the efficacy and safety…